Swiss neurotech Indivi acquires Cogitat to advance AI-powered brain monitoring

The acquisition brings Cogitat’s EEG foundation model NeuroRVQ into Indivi’s platform, aiming to detect early signs of treatment response in Alzheimer’s disease and other neurological conditions.
Swiss neurotech Indivi acquires Cogitat to advance AI-powered brain monitoring

Neurotech company Indivi has acquired Cogitat, an Imperial College London spin-out developing cutting-edge deep learning models that decode cognitive function from EEG brain signals.

Indivi is a neurotech company headquartered in Basel, Switzerland, with offices in Córdoba, Spain and Boston, Massachusetts. Indivi combines precision measurement, advanced analytics, and scientific expertise to help biopharmaceutical sponsors design smaller early-phase trials and detect treatment effects with greater confidence.

Its multimodal platform currently includes smartphone-based motor and cognitive assessments, with work spanning Parkinson’s disease, neuromuscular diseases including facioscapulohumeral muscular dystrophy (FSHD), multiple sclerosis, and Alzheimer’s disease and related dementias. 

Cogitat’s EEG foundation model, NeuroRVQ, powers brainwave decoders that are designed to work on anyone and on any device, with the goal of doing for the brain what large language models do for language.   

According to Guilhem Dupont, CEO and Founder of Indivi, the brain is the most complex organ in the body, and remains one of the hardest to understand and measure. 

“Cogitat’s EEG foundation model changes that, decoding brain activity and revealing signals far closer to the underlying biology than ever before.

That opens up exciting opportunities: initially the potential to provide drug developers earlier data on how new treatments are working for brain conditions, and, in the long-term, could inform the future development of next-generation brain health technologies beyond life sciences.”

Allan Ponniah, CEO and Founder of Cogitat, added: 

“Every brain is unique and speaks its own language. We’ve built an advanced AI model that works across every brain’s unique language without individual training to identify subtle changes in brain activity that have not been easily identifiable before.  

This addresses one of neuroscience’s biggest translational gaps: the failure to detect early changes in brain biology that predict whether a treatment or product will actually work."

Indivi will work with Cogitat’s world-class AI and scientific team to continue developing the foundation model, which captures fine detail in brain signals that other models may miss. 

Combined with Indivi’s leading edge in precision measurement, it will help detect the effects of experimental Alzheimer’s treatments, strengthening research and development across the life sciences. 
Looking ahead, the model could power new healthcare and consumer applications by turning EEG brain data into actionable insight.

Indivi’s next step: Foundation models informing treatment efficacy in Alzheimer's and related dementias

Indivi expects NeuroRVQ’s AI-driven approach to change how scientists and biopharma companies measure whether brain disease treatments, like Alzheimer's, are working.

Over time, this could help sharpen clinical trials and speed effective treatments to market. EEG offers a more direct window into brain activity, with the potential to detect changes before memory and thinking problems become clinically visible.

Cogitat’s EEG foundation model, NeuroRVQ, learns the patterns of brain activity and preserves the fine, fast-changing detail that most models discard. Indivi aims to use this to pick up subtler signs of disease and treatment response than existing methods can detect.


Follow the developments in the technology world. What would you like us to deliver to you?
Your subscription registration has been successfully created.